We can’t show the full text here under this license. Use the link below to read it at the source.
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: H igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
Treatment use in type 2 diabetes patients using GLP-1 medicines: Higher adherence and continued use with dulaglutide compared to once-weekly exenatide and liraglutide
AI simplified
Abstract
Mean adherence was significantly higher for dulaglutide at 0.72 compared to 0.61 for exenatide once weekly and 0.71 for liraglutide.
- The percentage of patients achieving at least 80% adherence was significantly higher for dulaglutide (54.2%) than for exenatide once weekly (37.9%) and liraglutide (53.5% vs 44.3%).
- Patients on dulaglutide had a mean of 148.4 days on treatment, significantly higher than those on exenatide once weekly (123.6 days) and liraglutide (146.0 days).
- Discontinuation rates were lower for dulaglutide (26.2%) compared to exenatide once weekly (48.4%) and liraglutide (28.0% vs 35.6%).
- Dulaglutide users demonstrated greater persistence and adherence over a 6-month follow-up period compared to those using exenatide or liraglutide.
AI simplified
Key numbers
0.72
Adherence Rate Increase
Mean PDC for dulaglutide vs. exenatide once weekly (0.61) and liraglutide (0.67)
26.2%
Discontinuation Rate Decrease
Percentage of patients discontinuing treatment: dulaglutide vs. exenatide once weekly (48.4%) and liraglutide (28.0%)
148.4
Days on Treatment Increase
Mean days on treatment for dulaglutide vs. exenatide once weekly (123.6) and liraglutide (146.0)